放射性核素131I标记纳米材料在恶性肿瘤诊疗中的应用

Application of radionuclide 131I labeled nanomaterials in the diagnosis and treatment of malignant tumor

  • 摘要: 恶性肿瘤严重威胁人类健康,其早期诊断与治疗是提高肿瘤患者生存率的关键因素,核医学纳米载体系统的出现满足了现阶段医学科研及临床医学对恶性肿瘤诊疗的需求。用放射性核素131I标记纳米材料,可充分利用纳米材料粒径小、表面可修饰等优点,实现肿瘤形成过程中关键分子可视化,从而实现早期诊断的目标。与此同时,还可最大程度地提高131I的靶向浓度,将放射性核素本身的治疗效果发挥至最佳,开创了肿瘤诊疗一体化的新模式。笔者拟对放射性核素131I标记不同纳米材料在肿瘤诊疗中的应用进行综述。

     

    Abstract: Malignant tumor is a serious threat to human health, and its early diagnosis and treatment is the key factor to improve the survival rate of cancer patients. The nanocarrier system of nuclear medicine then comes into being, which meets the needs of medical research and clinical medicine on malignant tumor diagnosis and treatment at the present stage. By labeling nanomaterials with radionuclide 131I, the advantages of nanomaterials, such as small particle size and surface modification, can be fully utilized to realize visualization of key molecules in the process of tumor formation, so as to achieve the goal of early diagnosis. At the same time, the targeted concentration of 131Ican be increased to the greatest extent, and the therapeutic effect of radionuclides themselves can be maximized, thus creating a new model of tumor diagnosis and treatment integration. The application of different nanomaterials labeled with radionuclide 131I in tumor diagnosis and treatment was reviewed.

     

/

返回文章
返回